Steve Chesney's Stock Ratings

Redburn Atlantic Analyst

Steve Chesney is an analyst at Redburn Atlantic. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 06/28/2024

Overall Average Return

-2.60%

Smart Score

51.2%

Overall Average Return Percentile

32nd

Number of Ratings

36
Buy NowGet Alert
06/27/2024VRTXBuy Now
Vertex Pharmaceuticals
$469.0016.2% → $545Initiates → BuyGet Alert
02/06/2024BMYBuy Now
Bristol-Myers Squibb
$41.6229.75%$77 → $54DowngradeBuy → NeutralGet Alert
08/08/2023BIIBBuy Now
Biogen
$231.8218.63%$282 → $275MaintainsNeutralGet Alert
08/04/2023JNJBuy Now
Johnson & Johnson
$146.2816.22%$167 → $170MaintainsNeutralGet Alert
08/02/2023IDXXBuy Now
IDEXX Laboratories
$487.2023.15% → $600DowngradeOverweight → NeutralGet Alert
07/28/2023BMYBuy Now
Bristol-Myers Squibb
$41.62104.23%$90 → $85MaintainsOverweightGet Alert
06/14/2023ZTSBuy Now
Zoetis
$173.5729.63% → $225ReiteratesOverweight → OverweightGet Alert
06/07/2023IDXXBuy Now
IDEXX Laboratories
$487.2023.15% → $600ReiteratesOverweight → OverweightGet Alert
05/26/2023ZTSBuy Now
Zoetis
$173.5729.63% → $225ReiteratesOverweight → OverweightGet Alert
05/03/2023IDXXBuy Now
IDEXX Laboratories
$487.2023.15% → $600Reiterates → OverweightGet Alert
05/01/2023MRKBuy Now
Merck & Co
$125.003.2%$127 → $129MaintainsOverweightGet Alert
04/26/2023BIIBBuy Now
Biogen
$231.8221.65%$295 → $282MaintainsNeutralGet Alert
04/19/2023JNJBuy Now
Johnson & Johnson
$146.2814.16%$168 → $167MaintainsNeutralGet Alert
03/07/2023MRKBuy Now
Merck & Co
$125.001.6%$122 → $127MaintainsOverweightGet Alert
02/10/2023ABBVBuy Now
AbbVie
$170.75-9.81%$157 → $154MaintainsNeutralGet Alert
02/07/2023IDXXBuy Now
IDEXX Laboratories
$487.2023.15%$470 → $600MaintainsOverweightGet Alert
02/03/2023BMYBuy Now
Bristol-Myers Squibb
$41.62116.24%$88 → $90MaintainsOverweightGet Alert
02/01/2023PFEBuy Now
Pfizer
$27.9764.46%$50 → $46MaintainsNeutralGet Alert
01/25/2023JNJBuy Now
Johnson & Johnson
$146.2814.85%$160 → $168MaintainsNeutralGet Alert
12/01/2022BIIBBuy Now
Biogen
$231.8227.25%$220 → $295MaintainsNeutralGet Alert
11/10/2022BMYBuy Now
Bristol-Myers Squibb
$41.62111.44%$85 → $88MaintainsOverweightGet Alert
11/02/2022IDXXBuy Now
IDEXX Laboratories
$487.20-3.53%$490 → $470MaintainsOverweightGet Alert
10/31/2022ABBVBuy Now
AbbVie
$170.75-8.05%$162 → $157MaintainsNeutralGet Alert
10/28/2022MRKBuy Now
Merck & Co
$125.00-2.4%$116 → $122MaintainsOverweightGet Alert
10/27/2022BMYBuy Now
Bristol-Myers Squibb
$41.62104.23%$87 → $85MaintainsOverweightGet Alert
10/26/2022BIIBBuy Now
Biogen
$231.82-5.1%$200 → $220MaintainsNeutralGet Alert
10/19/2022JNJBuy Now
Johnson & Johnson
$146.289.38%$165 → $160MaintainsNeutralGet Alert
10/11/2022MRKBuy Now
Merck & Co
$125.00-7.2%$110 → $116MaintainsOverweightGet Alert
09/12/2022BMYBuy Now
Bristol-Myers Squibb
$41.62109.03%$83 → $87MaintainsOverweightGet Alert
08/09/2022AMGNBuy Now
Amgen
$312.45-41.75%$190 → $182MaintainsUnderweightGet Alert
08/03/2022IDXXBuy Now
IDEXX Laboratories
$487.200.57%$500 → $490MaintainsOverweightGet Alert
08/01/2022ABBVBuy Now
AbbVie
$170.75-5.12%$178 → $162MaintainsNeutralGet Alert
07/28/2022BMYBuy Now
Bristol-Myers Squibb
$41.6299.42%$82 → $83MaintainsOverweightGet Alert
07/20/2022JNJBuy Now
Johnson & Johnson
$146.2812.8%$174 → $165MaintainsNeutralGet Alert
07/13/2022MRKBuy Now
Merck & Co
$125.00-12%$105 → $110MaintainsOverweightGet Alert
02/08/2022IDXXBuy Now
IDEXX Laboratories
$487.2033.42% → $650Initiates → OverweightGet Alert

Recent Analyst Stock Rating News

This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Peeling Back The Layers: Exploring Bristol-Myers Squibb Through Analyst Insights
Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday
Piper Sandler raised the price target for Chegg, Inc. (NYSE: CHGG) from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market trading.
Ralph Lauren To Rally 17%? Here Are 10 Other Analyst Forecasts For Friday
Atlantic Equities raised the price target for Johnson & Johnson (NYSE: JNJ) from $167 to $170. Atlantic Equities analyst Steve Chesney maintained a Neutral rating. Johnson & Johnson shares rose 0.1% to $170.70 in pre-market trading.
Roku To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Friday
JP Morgan boosted the price target for Intel Corporation (NASDAQ: INTC) from $30 to $35. JP Morgan analyst Harlan Sur maintained an Underweight rating. Intel shares rose 6.8% to $36.91 in pre-market trading.
These Analysts Revise Price Targets On Biogen Following Q1 Results
Biogen Inc. (NASDAQ: BIIB) reported results for its first quarter.
DocuSign To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday
Wells Fargo cut the price target for Cheniere Energy, Inc. (NYSE: LNG) from $236 to $230. Wells Fargo analyst Michael Blum maintained an Overweight rating. Cheniere Energy shares fell 4.8% to close at $156.55 on Monday.
Union Pacific To Rally Over 11%? Here Are 10 Other Analyst Forecasts For Wednesday
Keybanc raised the price target for Reliance Steel & Aluminum Co. (NYSE: RS) from $225 to $235. Keybanc analyst Philip Gibbs maintained an Overweight rating. Reliance Steel shares fell 0.2% to close at $215.79 on Tuesday.
Bristol-Myers Squibb To Surge Over 10%? Plus Morgan Stanley Predicts $263 For L3Harris Technologies
Atlantic Equities boosted the price target on Bristol-Myers Squibb Company (NYSE: BMY) from $85 to $88. Atlantic Equities analyst Steve Chesney maintained the stock with an Overweight. Bristol-Myers Squibb shares fell 0.3% to close at $79.78 on Wednesday.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free